Merck: completes acquisition of Acceleron

(CercleFinance.com) - Merck announced on Monday that it has completed the acquisition of US biopharmaceutical company Acceleron, in a deal that will strengthen its portfolio in high blood pressure.


This is an important and strategic opportunity for the group, which will be able to continue to grow its projects in cardiovascular treatments, Merck said.

Specialising in the engineering of TGF-beta proteins, Acceleron has developed sotatercept for the treatment of pulmonary arterial hypertension (PAH), an experimental drug that has now entered Phase III trials.

Merck announced a takeover bid for Acceleron Pharma last month in a deal worth around 10.9 billion dollars.


Copyright (c) 2021 CercleFinance.com. All rights reserved.